Fig. 5
Potential targets for an epi-drug co-treatment. A Potential targets for co-treatment identified via PINA analysis of genes (> log24) upregulated by an epi-drug treatment [51]. B qRT-PCR validation of upregulation of potential co-treatment target genes after low dose treatment with 0.2 × EC50 and 0.5 × EC50 and EC50 for comparison. Quisinostat: 0.2 × EC50: 0.35 nM, 0.5 × EC50: 0.88 nM, EC50: 1.76 nM; Chaetocin: 0.2 × EC50: 34.64 nM, 0.5 × EC50: 86.60 nM, EC50: 173.2 nM; GSK343: 0.2 × EC50: 2.14 µM, 0.5 × EC50: 5.36 µM; EC50: 10.71 µM). Asterisks indicate significant changes between treatment and solvent control (*p < 0.05, **p < 0.005). C Decrease in cell viability of mono versus combination treatment of indicated drugs . Cells were pretreated with the 0.5 × EC50 concentration of each epi-drug for 24 h, followed by treatment with different concentrations of the co-drug for 24 h and 48 h. Differences in cell viability are given in relation to the solvent controls. Raw data is given in Additional file 10: Fig. S10A. Asterisks indicate significant changes between double and both mono-treatments (*p < 0.05, **p < 0.005)